Laboratory testing is a critical component of surveillance for ZIKV infection due to co-circulation of DENV and CHIKV that cause similar symptoms.
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To determine regional capacity for ZIKV detection, the WHO Regional Office for the Western Pacific initiated a voluntary, rapid survey among national-level public health laboratories in its countries and areas (areas are non-sovereign jurisdictions within a WHO region; 9 countries and areas are together referred to as "countries" in this article). The survey sought to assess preparedness for ZIKV testing in the context of co-circulating DENV and CHIKV. Questions primarily addressed in-country capacity for molecular and serological detection of the three arboviruses, additional laboratory capacities specific for ZIKV and testing-related services to other countries.
The 19-question, email-based survey was administered between 2 and 23 February 2016, immediately following the PHEIC declaration. A total of 28 surveys to national-level laboratories likely to be tasked with ZIKV testing were distributed to 19 countries in the Region (omitting resource-limited countries with Zika virus testing preparedness in the Western Pacific Region Squires & Konings reporting having this capacity. Twelve countries indicated that they were willing to accept international specimens to supplement the capacity in other countries or for confirmation testing (data not shown).
Given the similarity of disease presentation, 1 co-circulation and increasing prevalence of infection,
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differential diagnosis for DENV, CHIKV and ZIKV is crucial. Molecular detection of DENV and CHIKV was in place in 17/19 (89.5%) countries, and a similarly large majority could perform serological diagnosis of DENV (17/19, 89.5%) and CHIKV (16/19, 84.2%) infection by IgM and/or IgG detection. The algorithm followed for differential diagnosis should take into consideration the endemic circulation of DENV, CHIKV and ZIKV. rely mainly on specimen referral, the study's geographic coverage only included countries of the Asian sub-region and larger countries or referral hubs of the Pacific subregion such as Australia and French Polynesia.
The laboratory plays an important role in improving our understanding of ZIKV epidemiology. While this survey reveals a broad availability of molecular diagnostics to support surveillance of ZIKV in the Western Pacific Region, further key roles remain for laboratories in helping to unravel the pathogenicity of the virus and its potential causal role in the observed cases of microcephaly and other neurological disorders.
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for the Americas guidance. 13 The remaining country indicated that the epidemiological circumstances of each case drove the specific algorithm followed.
This survey, conducted immediately following the WHO declaration of a PHEIC surrounding clusters of microcephaly and neurological disorders in the context of ZIKV infection, suggests that robust coverage for molecular detection of priority arboviruses is in place in the Region. Molecular detection by PCR is the critical differential diagnostic tool in this public health event as serology is problematic due to antibody cross-reactivity in regions with multiple circulating flaviviruses and/or use of vaccines against those viruses (for example, Japanese encephalitis virus).
7, 8 Other methodologies, such as the plaque reduction neutralization test (PRNT), exist for the specific serological discrimination among the flaviviruses but require significant technical expertise for accurate execution and would not be practical for large-scale surveillance. Only three of the countries responding to the survey reported they could perform PRNT (data not shown). While the Region seems prepared overall for testing of ZIKV, it is important to continue strengthening the apparatus for detection particularly through ensuring testing proficiency by EQA participation and enhancing referral mechanisms and International Air Transport Association certification where needed. It should be noted that while the EQA for DENV and CHIKV diagnostics gives confidence about regional testing proficiency for those arboviruses, 16 proficiency of ZIKV diagnostics remains untested. Note also that by omitting countries known to
